Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Toll-like receptor 2 induced cytotoxic T-lymphocyte-associated protein 4 regulates Aspergillus-induced regulatory T-cells with pro-inflammatory characteristics.

Raijmakers RPH, Sprenkeler EGG, Aleva FE, Jacobs CWM, Kanneganti TD, Joosten LAB, van de Veerdonk FL, Gresnigt MS.

Sci Rep. 2017 Sep 13;7(1):11500. doi: 10.1038/s41598-017-11738-4.

2.

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.

Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J.

Rheumatol Ther. 2017 Dec;4(2):489-502. doi: 10.1007/s40744-017-0078-y. Epub 2017 Aug 22.

3.

Treatment with Biologicals in Rheumatoid Arthritis: An Overview.

Rein P, Mueller RB.

Rheumatol Ther. 2017 Dec;4(2):247-261. doi: 10.1007/s40744-017-0073-3. Epub 2017 Aug 22. Review.

4.

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo.

Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, Liang JG, Shore G, Wang X, Liang P.

Sci Rep. 2017 Aug 21;7(1):8953. doi: 10.1038/s41598-017-09518-1.

5.

A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.

Nakagawa J, Koyama Y, Kawakami A, Ueki Y, Tsukamoto H, Horiuchi T, Nagano S, Uchino A, Ota T, Akahoshi M, Akashi K.

Arthritis Res Ther. 2017 Aug 11;19(1):185. doi: 10.1186/s13075-017-1387-9.

6.

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.

Li P, Zheng Y, Chen X.

Front Pharmacol. 2017 Jul 12;8:460. doi: 10.3389/fphar.2017.00460. eCollection 2017. Review.

7.

Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.

Gmyrek GB, Pingel J, Choi J, Green JM.

Cell Immunol. 2017 Sep;319:28-34. doi: 10.1016/j.cellimm.2017.07.002. Epub 2017 Jul 10.

PMID:
28711152
8.

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.

Szentpetery A, Heffernan E, Gogarty M, Mellerick L, McCormack J, Haroon M, Elmamoun M, Gallagher P, Kelly G, Fabre A, Kirby B, FitzGerald O.

Arthritis Res Ther. 2017 Jul 5;19(1):158. doi: 10.1186/s13075-017-1364-3.

9.

T Helper 17 Cells in Primary Sjögren's Syndrome.

Matsui K, Sano H.

J Clin Med. 2017 Jul 5;6(7). pii: E65. doi: 10.3390/jcm6070065. Review.

10.

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.

Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D.

Mediators Inflamm. 2017;2017:8909834. doi: 10.1155/2017/8909834. Epub 2017 Jun 1. Review.

11.

Targeting the programmed cell death-1 pathway in rheumatoid arthritis.

Sandigursky S, Silverman GJ, Mor A.

Autoimmun Rev. 2017 Aug;16(8):767-773. doi: 10.1016/j.autrev.2017.05.025. Epub 2017 May 29. Review.

PMID:
28572054
12.

Boi-ogi-to (TJ-20), a Kampo Formula, Suppresses the Inflammatory Bone Destruction and the Expression of Cytokines in the Synovia of Ankle Joints of Adjuvant Arthritic Rats.

Zhang X, Wu Z, Liu Y, Ni J, Deng C, Zhao B, Nakanishi H, He J, Yan X.

Evid Based Complement Alternat Med. 2017;2017:3679295. doi: 10.1155/2017/3679295. Epub 2017 May 7.

13.

Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.

Crepeau RL, Ford ML.

Expert Opin Biol Ther. 2017 Aug;17(8):1001-1012. doi: 10.1080/14712598.2017.1333595. Epub 2017 May 30. Review.

PMID:
28525959
14.

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights.

Krakauer T.

Immunotargets Ther. 2017 May 2;6:17-29. doi: 10.2147/ITT.S125429. eCollection 2017. Review.

15.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

16.

Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.

Araki Y, Mimura T.

Int J Mol Sci. 2017 Apr 25;18(5). pii: E905. doi: 10.3390/ijms18050905. Review.

17.

Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Kean LS, Turka LA, Blazar BR.

Immunol Rev. 2017 Mar;276(1):192-212. doi: 10.1111/imr.12523. Review.

PMID:
28258702
18.
19.

Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study.

Balandraud N, Texier G, Massy E, Muis-Pistor O, Martin M, Auger I, Guzian MC, Guis S, Pham T, Roudier J.

PLoS One. 2017 Feb 15;12(2):e0171623. doi: 10.1371/journal.pone.0171623. eCollection 2017.

20.

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.

Svedbom A, Dalén J, Black CM, Kachroo S.

Patient Prefer Adherence. 2017 Jan 16;11:95-106. doi: 10.2147/PPA.S119808. eCollection 2017.

Supplemental Content

Support Center